Covered recipient · General Payments record
COURTNEY BOWERS
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$1,917.40
- Reported across 96 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $695.06 | 34 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $184.56 | 10 |
| Lilly USA, LLC | $160.17 | 9 |
| ABBVIE INC. | $152.01 | 6 |
| Acerta Pharma LLC | $67.38 | 3 |
| Amgen Inc. | $39.47 | 2 |
| Astellas Pharma US Inc | $29.79 | 1 |
| Axsome Therapeutics, Inc. | $21.62 | 1 |
| Indivior Inc. | $21.56 | 1 |
| PFIZER INC. | $18.50 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (34)
Sorted by paying entity, then date · as published by CMS
Program year 2024 202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $10.18 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106806788 | CMS |
| ABBVIE INC. | $34.69 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106806790 | CMS |
| ABBVIE INC. | $10.88 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106806792 | CMS |
| ABBVIE INC. | $34.69 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106806794 | CMS |
| ABBVIE INC. | $34.54 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106806796 | CMS |
| ABBVIE INC. | $27.03 | 10/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106806798 | CMS |
| Amgen Inc. | $17.27 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117511753 | CMS |
| Amgen Inc. | $22.20 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117511755 | CMS |
| Astellas Pharma US Inc | $29.79 | 05/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139511407 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.82 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104613802 | CMS |
| AstraZeneca Pharmaceuticals LP | $32.97 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105233130 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.59 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105556544 | CMS |
| Axsome Therapeutics, Inc. | $21.62 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148349986 | CMS |
| Indivior Inc. | $21.56 | 05/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144544969 | CMS |
| Lilly USA, LLC | $20.68 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135601459 | CMS |
| Lilly USA, LLC | $5.60 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135601461 | CMS |
| Lilly USA, LLC | $0.65 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135601463 | CMS |
| Lilly USA, LLC | $22.38 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135618069 | CMS |
| Lilly USA, LLC | $18.29 | 06/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135629835 | CMS |
| Lilly USA, LLC | $23.70 | 08/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135593274 | CMS |
| Lilly USA, LLC | $18.74 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135594048 | CMS |
| Lilly USA, LLC | $18.48 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135593276 | CMS |
| Lilly USA, LLC | $31.65 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135608339 | CMS |
| Novo Nordisk Inc | $15.54 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100635265 | CMS |
| Novo Nordisk Inc | $17.09 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100378579 | CMS |
| Novo Nordisk Inc | $16.43 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100324936 | CMS |
| Novo Nordisk Inc | $16.49 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100360988 | CMS |
| Novo Nordisk Inc | $19.07 | 06/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100496751 | CMS |
| Novo Nordisk Inc | $22.13 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100488841 | CMS |
| Novo Nordisk Inc | $22.87 | 08/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100266694 | CMS |
| Novo Nordisk Inc | $13.07 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100227028 | CMS |
| Novo Nordisk Inc | $17.49 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100270995 | CMS |
| Novo Nordisk Inc | $24.38 | 12/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100537824 | CMS |
| PFIZER INC. | $18.50 | 08/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131833394 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.